← Back to Screener
MapLight Therapeutics, Inc. Common Stock (MPLT)
Price$28.34
Favorite Metrics
Price vs S&P 500 (4W)61.63%
Market Capitalization$1.28B
All Metrics
Price vs S&P 500 (YTD)66.94%
10-Day Avg Trading Volume0.30M
EPS (Annual)$-1.87
ROI (Annual)-67.35%
Cash / Share (Quarterly)$1.46
ROA (Last FY)-56.66%
Cash Flow / Share (Annual)$-1.92
P/B Ratio20.00x
Net Income / Employee (Annual)$-1
EPS Incl Extra (Annual)$-1.87
Current Ratio (Annual)7.20x
Quick Ratio (Quarterly)4.04x
3-Month Avg Trading Volume0.25M
52-Week High$31.13
EPS Excl Extra (Annual)$-1.87
Quick Ratio (Annual)6.83x
13-Week Price Return60.18%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.89x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.63
3-Month Return Std Dev75.54%
ROE (Last FY)-67.35%
EPS Basic Excl Extra (Annual)$-1.87
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Year-to-Date Return71.08%
5-Day Price Return14.22%
EPS Normalized (Annual)$-1.87
Month-to-Date Return47.81%
EBITD / Share (Annual)$-1.94
Price vs S&P 500 (13W)57.32%
Beta2.04x
52-Week Low$12.24
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.40
4.40
4.40
4.36
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MPLTMapLight Therapeutics, Inc. Common Stock | — | — | — | — | $28.34 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
MapLight Therapeutics is a biopharmaceutical company developing circuit-specific treatments for central nervous system disorders, targeting unmet needs in psychiatry and neuroscience. The company's differentiated approach focuses on targeting specific neural circuits rather than broad CNS pathways. Its pipeline includes multiple clinical-stage candidates, including ML-007C-MA, ML-004, ML-021, and ML-009.